Restart Life Sciences (CSE: HEAL; FSE: HN30; OTC Pink: NMLSF) has announced the appointment of capital markets veteran, Lindsay Hamelin, as an independent director on its board of directors (BoD), effective immediately.
Ms. Hamelin brings more than 20 years of capital markets and corporate finance experience, with expertise in corporate structuring, mergers and acquisitions, and financing strategies within public company environments.
In a statement, Steve Loutskou, CEO of Restart, commented, “We are very pleased to welcome Lindsay to the Board. Her 20-year track record in capital markets and M&A provides us with the high-level oversight needed for our next phase of strategic growth. Her perspective will be highly valuable as we continue to evaluate strategic opportunities and execute on our expansion within the ‘better-for-you’ functional food and CPG markets.”
